Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.53 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | BLVRB | P30043 | 1/20 | 0.51 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588218 | 0.92 | XDH (0.45) | XDHSLC22A12ABCC4ABCB11PGR | |
| SCHEMBL3589210 | 0.88 | KDM4E (0.52) | XDH | |
| SCHEMBL3583816 | 0.88 | XDH (0.66) | XDHSLC22A12ABCC4ABCB11PGR | |
| SCHEMBL3590048 | 0.87 | XDH (0.53) | XDH | |
| SCHEMBL3584941 | 0.86 | KDM4E (0.42) | XDH | |
| SCHEMBL3582234 | 0.85 | KDM4E (0.44) | XDH | |
| SCHEMBL13545894 | 0.84 | KDM4E (0.50) | — | |
| SCHEMBL3584935 | 0.83 | KDM4E (0.48) | XDH | |
| SCHEMBL3591093 | 0.83 | KDM4E (0.47) | XDH | |
| SCHEMBL3590470 | 0.83 | KDM4E (0.44) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | XDH 1/4885SLC22A12 292/4885ABCC4 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.